Treatment of ultralong-segment Barrett’s using focal and balloon-based radiofrequency ablation
- 157 Downloads
Endoscopic radiofrequency ablation (ERFA) is being evaluated as definitive treatment for patients with Barrett’s esophagus (BE). Guidelines have yet to be developed for the application of this technology to patients with ultralong-segment BE (ULBE, ≥8 cm). This study reports a single institution’s experience with ERFA of ULBE.
A retrospective review of patients with ULBE undergoing ERFA from August 2005 to February 2009 was conducted. The entire segment of intestinal metaplasia (IM) was treated at each session using balloon- and/or plate-based devices (BARRX Medical, Inc., Sunnyvale, CA). Retreatments, endoscopic mucosal resection (EMR), dilations, and biopsies were performed based on endoscopic findings. Surveillance was conducted according to standard guidelines.
Twenty-five patients (22 male) with a median age of 66 years [interquartile range (IQR) 57–74 years] were included. The length of BE treated was 10 cm (median; IQR 8–12 cm). Intramucosal carcinoma (IMC) was present in 3 patients, 15 had high-grade dysplasia (HGD), 6 had low-grade dysplasia (LGD), and 1 had IM without dysplasia. Complications for all 25 patients included hemorrhage (n = 1), stricture (n = 2), and nausea and vomiting (n = 2). Time from the initial procedure was such that 15 patients had postablation biopsies at least once. One patient with biopsies elected to undergo esophagectomy. Of these patients, 78.5% (11/14) had complete response (CR; no residual IM), two patients regressed from HGD to IM, and one patient with IMC had residual HGD and was treated with repeat EMR. The number of ablations in this group was 2.5 (median, IQR 2–3) during a median follow-up time of 20.3 months (IQR 10.4–29.2 months).
ERFA is safe and feasible in patients with ULBE and can be applied to the entire length of IM during one session. Eradication of BE can be achieved with few repeat ablations and continued, vigilant surveillance.
KeywordsBarrett’s esophagus Radiofrequency ablation Long segment Barrett’s Endoscopic therapy
- 24.Overholt BF, Lightdale CJ, Wang KK, Canto MI, Burdick S, Haggitt RC et al (2005) Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 62:488–498CrossRefPubMedGoogle Scholar
- 28.Sharma P, Wani S, Weston AP, Bansal A, Hall M, Mathur S et al (2006) A randomised controlled trial of ablation of Barrett’s oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results. Gut 55:1233–1239CrossRefPubMedGoogle Scholar
- 36.Gondrie JJ, Rygiel AM, Sondermeijer C, Fockens P, Ten Kate FJ, Krishnadath KK et al (2007) Balloon-based circumferential ablation followed by focal ablation of Barrett esophagus containing high-grade dysplasia effectively removes all genetic alterations. Gastroenterology 132:A64Google Scholar
- 38.Shaheen NJ, Sharma P, Overholt BF, Lightdale CJ, Wolfsen HC, Sampliner RE et al (2008) A randomized, multicenter, sham-controlled trial of radiofrequency ablation (RFA) for subjects with Barrett’s esophagus (BE) containing dysplasia: Interim results of the aim dysplasia trial. Gastroenterology 134:A37CrossRefGoogle Scholar
- 48.Velanovich V (2009) Endoscopic endoluminal radiofrequency ablation of Barrett’s esophagus: initial results and lessons learned. Surg Endosc [Epub ahead of print]Google Scholar